Associated Papers
A scalable approach to resolving variants of uncertain significance.
Tejura M et al.
Biorxiv : the Preprint Server for Biology, 2026
Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project.
Bossé Y et al.
Lung Cancer (amsterdam, Netherlands), 2025
VarMeter2: An enhanced structure-based method for predicting pathogenic missense variants through Mahalanobis distance.
Ohno S et al.
Computational and Structural Biotechnology Journal, 2025
Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance.
Bortolot M et al.
International Journal of Molecular Sciences, 2024
Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations.
Wang W et al.
Innovation (cambridge (mass.)), 2024
Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature.
Chaudhary HA et al.
Drugs in R&d, 2024
Resolving Discrepancies in Idylla BRAF Mutational Assay Results Using Targeted Next-Generation Sequencing.
George GV et al.
Genes, 2024
Outcomes of non-small cell lung cancer patients with non-V600E BRAF mutations: a series of case reports and literature review.
Lazar R et al.
Frontiers in Oncology, 2024
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Comparison of genomic profiling of circulating tumor DNA in pancreaticobiliary malignancies in plasma and bile.
Ohyama H et al.
Cancer, 2023
Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory.
Bhai P et al.
Frontiers in Oncology, 2023
Ongoing progress in BRAF-mutated non-small cell lung cancer.
Abdayem P et al.
Clinical Advances in Hematology & Oncology : H&o, 2022
Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
Riudavets M et al.
Lung Cancer (amsterdam, Netherlands), 2022
Clinically actionable cancer somatic variants (CACSV): a tumor interpreted dataset for analytical workflows.
Sobahy TM et al.
Bmc Medical Genomics, 2022
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers.
Murciano-Goroff YR et al.
British Journal of Cancer, 2022
[Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer].
Zhang H et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2022
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).
Tabbò F et al.
Cancer Treatment Reviews, 2022
Lysine acetylation regulates the interaction between proteins and membranes.
Okada AK et al.
Nature Communications, 2021
Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor‒Like Melanoma.
Muniz TP et al.
The Journal of Investigative Dermatology, 2021
Clinical and molecular spectra of BRAF-associated RASopathy.
Lee Y et al.
Journal of Human Genetics, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
Swimming toward solutions: Using fish and frogs as models for understanding RASopathies.
Patterson VL et al.
Birth Defects Research, 2020
BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.
Boyle EM et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
Comparison of hair manifestations in cardio-facio-cutaneous and Costello syndromes highlights the influence of the RAS pathway on hair growth.
Urban J et al.
Journal of the European Academy of Dermatology and Venereology : Jeadv, 2020
The paradox of cancer genes in non-malignant conditions: implications for precision medicine.
Adashek JJ et al.
Genome Medicine, 2020
Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer.
Mu Y et al.
Frontiers in Oncology, 2020
PEDIA: prioritization of exome data by image analysis.
Hsieh TC et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2019
Comparative analysis of functional assay evidence use by ClinGen Variant Curation Expert Panels.
Kanavy DM et al.
Genome Medicine, 2019
Analytical Evaluation of an NGS Testing Method for Routine Molecular Diagnostics on Melanoma Formalin-Fixed, Paraffin-Embedded Tumor-Derived DNA.
Mancini I et al.
Diagnostics (basel, Switzerland), 2019
Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.
Simarro J et al.
Cancers, 2019
BRAF Mutation Class and Clinical Outcomes-Response.
Dagogo-Jack I et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Scheffler M et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2019
An enhanced workflow for variant interpretation in UniProtKB/Swiss-Prot improves consistency and reuse in ClinVar.
Famiglietti ML et al.
Database : the Journal of Biological Databases and Curation, 2019
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.
Bolli N et al.
Leukemia, 2018
[Research Progress of Targeted Therapy for BRAF Mutation in Advanced Non-small Cell Lung Cancer].
Liu X et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2018
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
Dudnik E et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2018
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.
Leonetti A et al.
Cancer Treatment Reviews, 2018
Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.
Baik CS et al.
The Oncologist, 2017
BRaf signaling principles unveiled by large-scale human mutation analysis with a rapid lentivirus-based gene replacement method.
Lim CS et al.
Genes & Development, 2017
Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.
de Langen AJ et al.
Therapeutic Advances in Medical Oncology, 2017
Bioinformatics Approach for Prediction of Functional Coding/Noncoding Simple Polymorphisms (SNPs/Indels) in Human BRAF Gene.
Hassan MM et al.
Advances in Bioinformatics, 2016
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Gautschi O et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2015
USING SOMATIC MUTATION DATA TO TEST TUMORS FOR CLONAL RELATEDNESS.
Ostrovnaya I et al.
The Annals of Applied Statistics, 2015
RASopathies: unraveling mechanisms with animal models.
Jindal GA et al.
Disease Models & Mechanisms, 2015
Is diagnosing cardio-facio-cutaneous (CFC) syndrome still a challenge? Delineation of the phenotype in 15 Polish patients with proven mutations, including novel mutations in the BRAF1 gene.
Ciara E et al.
European Journal of Medical Genetics, 2015